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HIPECAbstract Background: For a long time peritoneal neoplasms were considered beyond surgical
intervention and beyond cure, till the concept of cytoreductive surgery (CRS) and adjuvant hyper-
thermic intraperitoneal chemotherapy (HIPEC) was introduced. However this surgical intervention
is technically demanding and associated with considerable postoperative morbidity.
Objective: To describe the surgical strategy in resection of critical sites loaded by heavy tumor
deposits and to evaluate short and long term results of CRS and HIPEC, in a cohort of Egyptian
patients with pseudomyxoma peritonei (PMP) from appendiceal origin.
Patients and methods: 21 patients with PMP, age ranged from 40 to 63 years, 12 males and 9
females. All were recruited from the department of surgery at the National Cancer Institute
(NCI), Cairo University over the period from February 2011 to February 2016. They were subjected
to CRS and HIPEC with mitomycin-C.
Results: The median peritoneal carcinoma index (PCI) was 22 (range: 10–39). Optimal cytoreduc-
tion (CCR-0/1) was achieved in 19 patients (90.4%) of whom 17 patients (80.9%) had a complete
cytoreduction (CCR-0). The median follow up period was 51.5 months (range: 0.07–82.3 months).
The cumulative overall survival was 85.7% while the cumulative disease free survival was 76.9%.
Conclusion: To the best of our knowledge, this is the first study reporting five years postoperative
outcome of CRS and HIPEC in Egyptian patients with PMP from appendiceal origin. Our results
support that although technically demanding this treatment modality is safe and associated with
favorable outcome.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
For a long time peritoneal neoplasms were considered beyond
surgical intervention and beyond cure, till the concept of
cytoreductive surgery (CRS) and adjuvant intraperitoneal
250 A.M.A. Mahmoud et al.chemotherapy was introduced [1]. The work was matured by
Sugarbaker in the 1990s, who developed a well-structured ther-
apeutic strategy combining macroscopic tumor removal
through cytoreduction and locoregional chemotherapy for
microscopic disease [2].
A mucinous appendicular tumor presenting with peritoneal
seedlings is the classic model of success for adopting this treat-
ment concept, which changed survival rates from zero to
approximately 80% [3–5].
However this surgical intervention is technically demand-
ing, challenging and associated with considerable postopera-
tive morbidity and so a systemic standardized surgical
approach is needed.Patients and methods
21 patients with psuedomyxoma peritonei from appendiceal
origin recruited from the department of surgery at the
National Cancer Institute (NCI), Cairo University over a per-
iod from February 2011 to February 2016. All patients pro-
vided informed consent and the study was approved by local
ethics committee. Patients’ demographics, pathological grade,
operative, postoperative outcomes and survival were recorded.
Performance status was measured by Eastern Cooperative
Oncology Group Scale. Pathological grading was performed
according to Misdraji classification.
Surgical procedure
The surgical technique for peritonectomy is described else-
where [2]; however there are three technically demanding
anatomical subsites especially when there is large tumor vol-
ume. The first site is when dissecting a tumor block surround-Figure 1 Resection of tumor block surrounding the liver. (a) Dissec
IVC. (c) Tumor is stripped by sharp dissection beneath Glisson’s capsing the liver (right subdiaphragmatic area, Gleeson capsule,
inferior surface of the liver and hepatorenal pouch): Starting
at the undersurface of the right hemidiaphragm, in the
extraperitoneal plane, the peritoneum is stripped exposing
the suprahepatic IVC till the bare area of the liver is encoun-
tered, then going in the counter direction from the liver side,
the tumor is stripped sharply beneath Glisson’s capsule going
till meeting the dissected tumor from the right hemidiaphragm
figure, so tumor can be resected enblock as an envelope
(Fig. 1). Before stripping a large tumor volume from the hep-
atorenal pouch and right subhepatic space, it is important first
to do Kocherization of the duodenum and identification of the
infrahepatic IVC, mobilization of the right lobe also adds for
safe tumor stripping after visualization of the infrahepatic
IVC, then dissection starts laterally on the right extraperi-
toneal plane to encounter the perirenal fat covering the right
kidney and the right adrenal gland which is carefully avoided.
The second technically demanding site is when confronting
with block of tumor in hilum of the liver: dissection starts with
retrograde cholecystectomy, tracing the cystic duct to identify
the common bile duct on the right side of the hepatoduodenal
ligament, then entering the lesser sac, identify the upper edge
of the pancreas and celiac axis, tracing the hepatic artery till
the hilum of the liver on the left side of the hepatoduodenal
ligament, this is followed by splitting the tumor and going in
clock and antilock direction to completely strip the tumor
from the posterior aspect of the hepatoduodenal ligament
(Fig. 2).
The third site is when dissecting a block of tumor in the
Douglas pouch or recto-vesical pouch, dissection starts with
identification and dissection of both ureters from the under
surface of the peritoneum till the vesicoureteric junction, filling
the bladder with 400 cc saline facilitating identification of the
proper plane and stripping the peritoneum from the bladdertion in the extrperitoneal plane. (b) Exposure of the suprahepatic
ule. (d) Tumor enblock specimen.
Surgical strategy in critical sites 251wall till the vagina or the prostate. The pararectal and retrorec-
tal spaces are further developed and dissected down to the level
of the pelvic floor, this helps posterior and lateral mobilization
of the rectum which moves the peritoneal reflection up, thus
facilitating stripping the peritoneum from the Douglas pouch
or recto vesical pouch from caudal to cephalic using sharp dis-
section (Fig. 3).
After complete cytoreduction, adjuvant hyperthermic
intraperitoneal chemotherapy (HIPEC) was performed using
the closed coliseum technique, the abdominal cavity was per-
fused for 90 min with isotonic dialysis fluid containing mito-
mycin C at a dose of 15–20 mg/m2 and heated to 42 C.
Hyperthermia can cause cytotoxicity with formation of heatFigure 2 Tumor resection from the hilum of the liver, (a) Tumor oblit
protection of the common bile duct and hepatic artery proper.
Figure 3 Tumor obliterating the Douglas pouch. (a) Stripping of ant
peritoneum. (c) Complete stripping of peritoneum covering the rectum
(enblock pelvic peritonectomy).shock proteins (HSP). Cancerous tissues exhibit altered ther-
moregulation and so massive cellular destruction occurs on
prolonged exposure to heat. In addition, hyperthermia can
enhance the cytotoxicity of mitomycin C. The extent of cytore-
duction was by the completeness of cytoreduction score (CCR)
graded CCR-0: no visible tumor; CCR-1: tumor tissue not
>0.25 cm, CCR-2: tumor tissue between 0.25 and 2.5 cm
and CCR-3: tumor tissue >2.5 cm. Postoperative complica-
tions were graded according to the Clavien-Dindo Classifica-
tion of surgical complications [6].
The role of adjuvant chemotherapy is questionable in low
grade and slowly progressing disease. Adjuvant chemotherapy
is offered only in higher grade disease, so five cases received theerating the liver hilum. (b) Tumor resection after identification and
erior pelvic peritoneum. (b) Complete stripping of urinary bladder
, both ureters are dissected and protected. (d) Surgical specimen
Table 1 Demographic, clinical and operative characteristics
of the studied series (n= 21).
Variable
Age (year) 51.8 ± 6.4
Female:male 9:12
Performance status score
0 8 (38%)
1 13 (61.9%)
Clinical presentation
Abdominal distension 14 (66.6%)
Appendicitis 5 (23%)
Abdominal pain 2 (9.5%)
Preoperative chemotherapy 7 (33%)
Previous surgery 5 (23%)
Pathologic classification
Low grade 16 (76.2%)
High grade 5 (23.8%)
Operative characteristics
Peritoneal carcinomatosis index 22 (10–39)
Completeness of cytoreduction score
CCR-0 17 (81.0%)
CCR-1 2 (9.5%)
CCR-2 2 (9.5%)
Hyperthermic intraperitoneal chemotherapy
Delivered 18 (85.7%)
Not delivered 3 (14.3%)
Operative time (h) 6 (4–8)
Blood loss (mL) 1500 (500–4000)
Data presented as mean ± SD, median (range) or number (%).
CC-0: no visible tumor, CC-1: tumor tissue not >0.25 cm, CC-2:
tumor tissue between 0.25 and 2.5 cm.
Table 2 Organ resection rate.
Organ Number (%)
Resection of small intestine 4 (19.0)
Right hemicolectomy 4 (19.0)
Anterectomy 2 (9.5)
Splenectomy 15 (71.4)
Cholecystectomy 14 (66.6)
Distal pancreatectomy 2 (9.5)
TAH & BSO (n= 12) 9 (100.0)
Appendectomy 16 (76.2)
Data presented as Number (%).
TAH & BSO: Total abdominal hysterectomy and bilateral salp-
ingo-oophorectomy.
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tabine 1 gm/m2 Day1–Day14, every 3 weeks for six months).
Otherwise we keep the patient under regular follow up.
Our strategy for follow up is periodic clinical examination
every 4 months in the first 2 years then every 6 months in the
next 3 years then yearly thereafter. CEA or CA19.9 may be
used with the clinical examination if initially elevated. Radio-
logic follow up is used when there is suspected clinical recur-
rence. Otherwise it is used routinely every 6 months in the
first year then yearly thereafter. The classic radiologic tool is
CT scan with IV and oral contrast.
The overall survival (OS) was calculated from date of diag-
nosis till date of death or last follow up. The Disease free sur-
vival (DFS) was calculated from date of operation till date of
relapse, date of death or date of last follow up.
Statistical methods
Numerical data were expressed as mean and standard devia-
tion or median and range as appropriate. Qualitative data were
expressed as frequency and percentage. Survival analysis was
done using Kaplan–Meier method.
Results
The mean age was 51.8 ± 6.4 years (range: 40–63 years). They
were 12 males and 9 females. The most frequent presentation
of the patients was abdominal distention which represents
66% of cases, other presentations and clinical characteristics
are present in Table 1.
At laparotomy, the median PCI was 22 (range: 10–39).
Optimal cytoreduction (CCR-0/1) was achieved in 19 patients
(90.4%) of whom 17 patients (80.9%) had a complete cytore-
duction (CCR-0). Other intraoperative characteristics are
shown in Table 1. Detailed organ resection rates are described
in the Table 2. HIPEC was delivered intraoperatively in 18
patients (85.7%) of which mitomycin C-based HIPEC was
delivered; HIPEC was not delivered due to developing of atrial
fibrillation (AF) in two patients and hemodynamic instability
in one.
The median operative time (surgery and HIPEC) was 6 h
(4–8). The median intraoperative blood loss was 1500 cc
(500–4000). Two patients had Grade 1 postoperative complica-
tions and one patient had Grade 2 (Table 3).
The median follow up period was 51.5 months (range 0.07–
82.3 months). At the end of the study only 3 cases died. The
cumulative overall survival was 85.7% (Fig. 6). Three cases
developed recurrence; two cases in the hepatorenal pouch
and the floor of lesser sac 12 and 18 months after primary sur-
gery respectively. Both patients were subjected to re-resection
and re-HIPEC (Figs. 4 and 5). In the third case of recurrence
(24 months after surgery), exploration revealed advanced and
disseminated tumor recurrence which was beyond resection.
The cumulative diseases free survival was 76.9% for (Fig. 7).
Discussion
The benign tumor behavior and innocent long natural history
of PMP from appendiceal origin with its slow progression rate
dictates its management. Aggressive intervention is justifiedregardless of tumor volume. The median peritoneal carcinoma
index (PCI) in our study was 22 (10–39).
Apart from small bowel and small bowel mesenteric heavy
tumor dissemination, CRS and HIPEC should be attempted in
all cases. D. Elias group [7] identified 3 limitations for CCRS
(1) to guaranty a sufficient length of residual small bowel (2)
to preserve the left gastric vessels in order to preserve the supe-
rior third of the stomach (3) to ensure that the hepatic pedicle
can be entirely cleared from its tumor involvement. None of
the other peritonectomy procedures were decisional for CCRS.
Table 3 Postoperative complications.
Variable Number Grade*
Atrial fibrillation (AF) 1 2
Atelectasis 1 1
Wound infection 2 1
Disseminated intravascular coagulopathy 1 5
Cardiogenic shock (complicated AF) 1 5
* According to the Clavien-Dindo classification of surgical
complications.
Surgical strategy in critical sites 253In spite of high median PCI (22), optimal CRS (CC0-CC1)
was obtained in 90.5%. Overall, the main predictive factor for
survival is the quality of the surgical resection, which is corre-
lated with the risk of early recurrence [8].
On the molecular level, absence of adhesive molecules and
lack of E-cadherin expression allows a relatively easy stripping
of a large tumor mass possible regardless the volume of the dis-
ease or its critical site, this limits the need for bowel resection
and so decreases the probability of intestinal fistula, the most
drastic and serious postoperative morbidity [9], the fistula rate
was zero in this study reflecting the low rate of small bowel
resection which was only 19.4%
Two main pathologic classifications have been described.
Ronnett et al. divided these tumors into three main groups:
namely, low-grade disseminated peritoneal adenomucinosis
(dpam), high-grade peritoneal mucinous carcinomatosisFigure 4 Tumor recurrence in the in the hepatorenal pouch. (a) CT sh
after mobilization of the right lobe of liver and dropping the right ad
Figure 5 Tumor recurrence in the floor of lesser sac and posterior w
lesser sac. (b) Tumor resection with distal gasterectomy.(PMCA), and intermediate-grade PMCA (PMCA-i). Misdraji
et al. described another classification designating appendiceal
tumors as either low-grade appendiceal mucinous neoplasms
or high-grade mucinous adenocarcinomas. The categories are
associated with different natural histories and thus different
outcomes [10–11].
In this study, according to Misdraji classification, 5 patients
(22.7%) were high grade and 16 patients (77.2%) were low
grade.
In spite of critical site heavy deposits, still enblock resection
with peritonectomy was possible in most of non-recurrent
cases. Great volume affection was observed in three anatomic
sites where the bowel is anchored to the retroperitoneum and
peristalsis causes less motion of the visceral peritoneal surface,
the rectosigmoid, the ileocecal valve, and the antrum of stom-
ach [12–13]. In this study all bulky tumors in rectosigmoid area
were shaved successfully, right hemicolectomy was done in 4
patients and 2 patients had distal gasterectomy.
CRS and HIPEC is an anesthetic challenge, two patients
developed atrial fibrillation (AF), one of them proceeded to
heart block and cardiogenic shock, three patients in these ser-
ies were not subjected to HIPEC after CRS due to anesthetic
consideration, so proper patient selection and preoperative
preparation is essential, a patient must be fit enough to
undergo this high-risk and lengthy procedure [14–15].
Two patients (9.5%) in this study had suboptimal cytore-
duction, data from 2298 treated patients with CRS and HIPECows tumoral recurrence in hepatorenal pouch. (b) Tumor resection
renal gland.
all of the stomach. (a) CT shows tumor recurrence in the floor of
Figure 6 The cumulative over all (OS) for the PMP group.
Figure 7 The cumulative diseases free survival (DFS) for the PMP group.
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important predictive factor for OS was the completeness of
cytoreduction. At 10-year, OS was indeed 67% after complete
resection (CCR 0-1) but 9% only after incomplete (CCR 2)
resections [16].
Re-resection and HIPEC is feasible in recurrent cases.
Three recurrent incidents occurred in this study, two in the per-
ihepatic site and one in the floor of lesser sac, two patients werereoperated and subjected to re-resection and HIPEC, the other
patient was found too advanced. So secondary CRS is consid-
ered safe and feasible [17–18]. These patients presented initially
with high PCI, high grade and previous exploration.
In this series, two early postoperative mortalities occurred,
secondary to complicated intraoperative arrhythmia and car-
diogenic shock, and disseminated intravascular coagulopathy
(DIC). This is compared favorably with international reports,
Surgical strategy in critical sites 255the overall morbidity after CRS and HIPEC is reported to be
12–56% and perioperative mortality between 0 and 12%, in
the literature [19–20].
In spite of aggressive diaphragmatic enblock resection with
peritonectomy we didn’t observe symptomatic pleural effusion
in our cases, which may be attributed to the small number of
patients included in this study, unlike that reported after
diaphragmatic stripping by Terauchi et al. [21].
The cumulative OS was 85.7% while the cumulative dis-
eases free survival (DFS) was 76.9% for the study group,
which is compared favorably with many reports [22–23].
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